Telo Genomics Corp (TELO) NPV

Sell:0.08 CADBuy:0.09 CAD0.01 CAD (6.25%)

Prices delayed by at least 15 minutes
Sell:0.08 CAD
Buy:0.09 CAD
Change:0.01 CAD (6.25%)
Prices delayed by at least 15 minutes
Sell:0.08 CAD
Buy:0.09 CAD
Change:0.01 CAD (6.25%)
Prices delayed by at least 15 minutes

Company Information

About this company

Telo Genomics Corp. is a molecular diagnostics company that is engaged in developing the telomere analysis platform Teloview to enable the development of diagnostic and prognostic applications based on the quantification of genomic instability as a disease predictor. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. It quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.

Key people

Guido Baechler
Executive Chairman of the Board
Sabine Mai
Interim Chief Executive Officer, Director, Chair of the Clinical and Scientific Advisory Board
Christopher Ross
Chief Financial Officer
John Farlinger
Director
Ron Mcglennen
Independent Director
John Meekison
Independent Director
Hugh Rogers
Independent Director
Click to see more

Key facts

  • EPIC
    TELO
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA87975M2085
  • Market cap
    CA$8.50m
  • Employees
    8
  • Shares in issue
    100.02m
  • Exchange
    TSX Venture Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.